| Autor: |
Yasuko Aoyagi, Yoshihito Kano, Kohki Tohyama, Shotaro Matsudera, Yuichi Kumaki, Kenta Takahashi, Takahiro Mitsumura, Yohei Harada, Akemi Sato, Hideaki Nakamura, Eisaburo Sueoka, Naoko Aragane, Koichiro Kimura, Iichiro Onishi, Akira Takemoto, Keiichi Akahoshi, Hiroaki Ono, Toshiaki Ishikawa, Masanori Tokunaga, Tsuyoshi Nakagawa, Noriko Oshima, Reiko Nakamura, Masatoshi Takagi, Takahiro Asakage, Hiroyuki Uetake, Minoru Tanabe, Satoshi Miyake, Yusuke Kinugasa, Sadakatsu Ikeda |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 17, Iss 3, p e0266112 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0266112 |
| Popis: |
IntroductionClinical sequencing has provided molecular and therapeutic insights into the field of clinical oncology. However, despite its significance, its clinical utility in Japanese patients remains unknown. Here, we examined the clinical utility of tissue-based clinical sequencing with FoundationOne® CDx and FoundationOne® Heme. Between August 2018 and August 2019, 130 Japanese pretreated patients with advanced solid tumors were tested with FoundationOne® CDx or FoundationOne® Heme.ResultsThe median age of 130 patients was 60.5 years (range: 3 to 84 years), and among them, 64 were males and 66 were females. Major cancer types were gastrointestinal cancer (23 cases) and hepatic, biliary, and pancreatic cancer (21 cases). A molecular tumor board had been completed on all 130 cases by October 31, 2019. The median number of gene alterations detected by Foundation testing, excluding variants of unknown significance (VUS) was 4 (ranged 0 to 21) per case. Of the 130 cases, one or more alterations were found in 123 cases (94.6%), and in 114 cases (87.7%), actionable alterations with candidates for therapeutic agents were found. In 29 (22.3%) of them, treatment corresponding to the gene alteration was performed. Regarding secondary findings, 13 cases (10%) had an alteration suspected of a hereditary tumor. Of the 13 cases, only one case received a definite diagnosis of hereditary tumor.ConclusionsOur study showed that clinical sequencing might be useful for detecting gene alterations in various cancer types and exploring treatment options. However, many issues still need to be improved. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
